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Osteoporosis is a major health problem; however, the mechanisms regulating adult bone 
mass are poorly understood. Cas-interacting zinc finger protein (CIZ) is a nucleocytoplasmic 
shuttling protein that localizes at cell adhesion plaques that form where osteoblasts attach 
to substrate. To investigate the potential role of CIZ in regulating adult bone mass, we 
examined the bones in CIZ-deficient mice. Bone volume was increased and the rates of bone 
formation were increased in CIZ-deficient mice, whereas bone resorption was not altered. 
CIZ deficiency enhanced the levels of mRNA expression of genes encoding proteins related 
to osteoblastic phenotypes, such as alkaline phosphatase (ALP) as well as osterix mRNA 
expression in whole long bones. Bone marrow cells obtained from the femora of CIZ-
deficient mice revealed higher ALP activity in culture and formed more mineralized nodules 
than wild-type cells. CIZ deficiency enhanced bone morphogenetic protein (BMP)–induced 
osteoblastic differentiation in bone marrow cells in cultures, indicating that BMP is the 
target of CIZ action. CIZ deficiency increased newly formed bone mass after femoral bone 
marrow ablation in vivo. Finally, BMP-2–induced bone formation on adult mouse calvariae 
in vivo was enhanced by CIZ deficiency. These results establish that CIZ suppresses the levels 
of adult bone mass through inhibition of BMP-induced activation of osteoblasts.
 
Osteoporosis is one of the major health prob-
lems in our modern society with respect to the
large number of patients as well as a huge
medical cost (1–3). Bone loss in bed-ridden
patients with age-related problems such as
cerebrovascular diseases or osteopenia due to
estrogen depletion after menopause increase
the risk of fractures (4–6). More importantly,
low levels of adult (peak) bone mass also in-
crease the risk of fractures. However, limita-
tion in the knowledge on the molecules acting
as signaling factors to determine adult bone
mass has hampered the progress in understand-
ing the mechanisms that control adult bone
mass levels.
Osteoblasts attach to bone and regulate ex-
tracellular environment, while they are also
controlled by bone via membrane-bound
attachment proteins, which form adhesion
plaques in these cells. These molecules are one
of the candidates to regulate osteoblasts by
conveying attachment signals from bone (7, 8).
Thus, bone matrix could give signals from
outside the body to the cells (9, 10) either
through matrix-residing cytokines, through
these attachment machineries, or both. Such
extracellular matrix-derived signals regulate
osteoblastic cell mostly, if not exclusively, via
transcriptional events (11–14). Therefore, mol-
ecules that could localize at adhesion plaques
and, at the same time, modulate transcription
in nuclei are intriguing candidates that partici-
pate in the regulation of osteoblastic function
and bone mass.
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Cas-interacting zinc finger protein (CIZ) is a nucleocy-
toplasmic shuttling protein and it was initially identified by
far-western screening of a rat 3Y1 cDNA library using SH3
domain of p130
 
cas
 
 as a probe (15). As expected based on its
interaction with p130
 
cas
 
, CIZ colocalizes with vinculin and
other adhesion-related proteins at adhesion plaques (15).
Interestingly, CIZ contains nuclear localization signal as well
as five to eight zinc fingers (15–17), binds to a consensus
sequence, (G/C)AAAAA, and activates transcription via
promoters of the genes encoding matrix metalloproteinases
such as MMP-7 (15).
CIZ is expressed in osteoblasts in culture. However, its
function has not yet been clear as CIZ overexpression in
vitro has been either reported to activate or to inhibit osteo-
blastic  activities depending on experimental conditions
(16, 18, 19). Thus, in vivo physiological function of CIZ in
bone has not yet been determined. To obtain insights into
the role of CIZ in bone in vivo, we investigated the bone in
the CIZ-deficient mice.
 
RESULTS
 
X-ray examinations of the bone revealed that gross mor-
phology of the femora in CIZ-KO mice was similar to that
in wild type (Fig. 1, A and B). Body weight in CIZ-KO
mice was 
 
 
 
10% less at the 8-wk time point, whereas it
caught up with the weight of wild-type mice by 50 wk (Fig.
1 C). X ray of the long bone revealed that trabecular spicules
present in the distal end of femora were observed to be
denser in CIZ-KO compared with wild type (Fig. 2 A).
Similarly, femoral neck (Fig. 2 A) was more radiopaque in
CIZ-KO compared with wild type. Radiopacity levels in
the distal ends of the femur (condyle regions) were similar
between the two genotypes (Fig. 2 A).
To further visualize the changes in the trabecular bone
structures in the femora, two-dimensional microCT exami-
nation was conducted in the metaphyseal regions of the fem-
ora within a midsagittal plane. This demonstrated that more
cancellous bone was present in the femora in CIZ-KO mice
than wild-type mice (Fig. 2 B). Quantification of the trabec-
ular bone on the microCT sections of the femora (Fig. 2 B,
rectangle) indicated that BV/TV levels were increased by
 
 
 
40% in CIZ-KO mice (Fig. 2 C). Increase was not limited
to long bones as microCT examination of the lumbar verte-
brae indicated 
 
 
 
15% increase in trabecular bone mass (Fig. 2,
D and E).
To examine whether CIZ deficiency–induced increase
in bone volume could be due to reduction in bone resorp-
tion, histomorphometric analysis was conducted to obtain
bone resorption parameters. Osteoclast morphology (not de-
picted) as well as quantitative bone resorption parameters,
including osteoclast number per bone surface (N.Oc/BS)
and osteoclast surface per bone surface (Oc.S/BS) in the his-
tological sections, were similar between wild-type and CIZ-
deficient mice (Fig. 3, A and B). Thus, bone resorption
would not be a major target of CIZ action. In contrast with
the bone resorption parameters, histomorphometry on bone
formation parameters in CIZ-deficient mice based on calcein
double labeling indicated that the bone formation rate and
mineral apposition rate were enhanced in CIZ-KO mice in
comparison with those in wild-type mice (Fig. 4, A–C).
Therefore, CIZ deficiency enhances specifically bone forma-
tion activity in vivo without altering bone resorption to
increase trabecular bone volume.
We further investigated whether CIZ deficiency en-
hances osteoblastic activity in a cell-autonomous manner.
For this purpose, bone marrow cells were obtained from the
femora of wild-type and CIZ-deficient mice and were cul-
tured in the presence of ascorbic acid and 
 
 
 
-glycerophos-
phate. Alkaline phosphatase (ALP) activity was measured after
10 d in cultures. Bone marrow cells from CIZ-KO mice
revealed higher basal levels ALP activity than the cells from
wild-type mice (Fig. 5).
To examine whether such CIZ deficiency–induced en-
hancement of ALP activity could be translated into alteration
in calcified tissue formation, nodule formation assays were
conducted. As shown in Fig. 6 A, CIZ deficiency enhanced
the formation of alizarin red–S-positive mineralized nodules
in the bone marrow cells in culture. Quantification of the al-
izarin red-positive nodules revealed approximately threefold
enhancement of the nodule formation in CIZ-deficient
Figure 1. Radiological examination of CIZ KO mice. (A) Soft X-ray 
image of WT mice. (B) Soft X-ray image of CIZ KO mice. (C) Time course 
of the body weight in CIZ-KO mice and wild-type mice. 
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bone marrow cells (Fig. 6 B). These data indicate that CIZ
deficiency enhances osteoblastic activity in a cell-autonomous
manner. We also performed bone marrow cultures to exam-
ine the effect of CIZ deficiency on osteoclastogenesis. CIZ
deficiency did not alter the levels of tartrate-resistant acid
phosphatase (TRAP)-positive multinucleated cell formation
in culture, indicating that CIZ deficiency does not target
cells in osteoclast lineage (Fig. 6 C).
To explore the molecular bases for CIZ deficiency–
induced enhancement in bone formation in vivo, we exam-
ined expression profile of osteoblastic phenotype-related
genes in the bone of these mice. Total RNA was extracted
from whole humeri and was subjected to RT-PCR analysis.
The mRNA expression levels of osteoblastic phenotype-
related genes such as type I collagen (COL), ALP, and os-
teopontin (OPN), as well as upstream transcription factor
gene, osterix (OSX), were enhanced in CIZ-KO mice (Fig. 7,
A and B). These data reveal that the increase in bone-form-
ing activity in the cells in CIZ-deficient mice in vivo at least
in part is based on the enhancement of expression of the
genes encoding osteoblastic phenotype-related proteins as
well as upstream osteoblastic transcription factor.
To examine the mechanism of how CIZ deficiency af-
fects osteoblastic activities, effects of CIZ deficiency on bone
morphogenetic protein (BMP) actions were examined in
vitro and in vivo. First, CIZ deficiency effects on BMP ac-
tions were examined in the bone marrow cells in culture.
ALP activity in wild-type bone marrow cells was enhanced
by approximately threefold by BMP treatment (100 ng/ml
recombinant human [rh]BMP-2 for 10 d; Fig. 8). Such
BMP-enhanced ALP activity levels in wild-type cells were
comparable to ALP activity levels in vehicle-treated CIZ-
deficient cells, indicating that the absence of CIZ per se re-
sulted in the enhancement of ALP levels as potently as BMP
Figure 2. Trabecular bone volume of the femora is increased in CIZ 
KO mice. (A) Soft X-ray image of the femora of WT and CIZ-KO mice. The 
two bones shown in A were subjected to X-ray exam on the same X-ray 
film and, therefore, X-ray exposure (power [i.e., volts/amperes], exposure 
time), developing solution, developing time, and temperature were exactly 
the same. Trabecular bone spicule, femoral neck, and condyle region are 
depicted. Two-dimensional microCT images of the midsagittal planes of 
the distal regions of the femora (B) or vertebrae (D) of WT and CIZ-KO mice. 
Fractional trabecular BV/TV was quantified based on the image analysis of 
two-dimensional microCT images of the femora (C) or vertebrae (E) of WT 
and CIZ-KO mice. Analyses were conducted in the rectangular area shown 
in B and D. Asterisk indicates statistically significant difference (P   0.05). 
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treatment. BMP treatment of CIZ-deficient cells further en-
hanced ALP levels up to threefold compared with those in
BMP-treated wild-type cells (up to ninefold compared with
vehicle-treated wild-type cells). Thus, for the same BMP
treatment, presence versus absence of CIZ resulted in one-
versus threefold increase in ALP activity levels, respectively,
indicating that CIZ deficiency enhances BMP effects in vitro
in a cell-autonomous manner.
Furthermore, we asked whether such in vitro CIZ defi-
ciency effects on BMP actions can be translated into bone
formation in vivo. For this purpose, bone marrow ablation
was conducted because BMP expression was reported to be
observed during bone regeneration in bone marrow ablation
experiments (20). Bone marrow ablation was performed on
the femora of wild-type and CIZ-KO mice, and the bones
were examined using two-dimensional microCT 10 d later.
Images of CIZ-deficient mice revealed denser newly formed
trabecular bone patterns in the ablated area in the femora af-
ter bone marrow ablation compared with wild type (Fig. 9
A, rectangular area). Quantification of the newly formed
trabecular bone (BV/TV) indicated that fractional bone
volume in wild-type mice was increased by 3.0-fold relative
to intact contralateral femora after ablation, whereas CIZ
deficiency enhanced the increase in fractional bone volume
by 3.7-fold relative to intact contralateral femora (Fig. 9 B,
P 
 
  
 
0.05), even though the basal intact bone mass levels
Figure 3. Quantification of the osteoclastic parameters in the 
trabecular bone of the femora of WT and CIZ-KO mice. Sections of 
the femora of WT and CIZ-KO mice were subjected to TRAP and Fast green 
staining followed by histomorphometry. (A) Quantification of N.Oc/BS in 
the bone marrow cavity of WT and CIZ-KO mice. (B) Quantification of 
Oc.S/BS in the bone marrow cavity of WT and CIZ-KO mice.
Figure 4. Bone formation rate and mineral apposition rate are 
increased in CIZ KO mice. (A) Cross sections of the femora of WT and 
CIZ-KO mice. Calcein labeling was conducted and labeled lines were visu-
alized and measurement was performed under fluorescent microscopy. 
(B) Quantification of bone formation rate (BFR) in the secondary spongiosa 
of WT and CIZ-KO mice. (C) Quantification of mineral apposition rate (MAR) 
in the secondary spongiosa of WT and CIZ-KO mice. Asterisks indicate 
statistically significant difference (P   0.05). 
JEM VOL. 201, March 21, 2005
 
965
 
ARTICLE
 
were higher than wild type. These observations indicate that
CIZ deficiency enhances new trabecular bone formation in
the ablation-induced bone regeneration model in vivo.
As the bone marrow ablation model does not specifically
address whether CIZ deficiency–induced in vivo bone for-
mation is through modulation of BMP actions alone or
through bone formation in response to a mixture of injury-
related cytokines, we tested whether CIZ deficiency en-
hances BMP-induced bone formation directly in vivo. 5 
 
 
 
g
rhBMP-2 was injected onto the calvariae of wild-type and
CIZ-KO mice to induce orthotopic bone formation. The
rhBMP-2 injection–induced de novo bone formation was
evaluated based on soft X-ray images using an image analyzer
and was expressed as the area of the newly formed bone. Di-
rect rhBMP-2 injection produced new bone, which was de-
tected on soft X-ray images as shown in Fig. 10 A (arrow).
Quantification of the area of the newly formed bone indi-
cated that approximately twofold greater bone was formed by
rhBMP-2 injection onto the calvariae of CIZ-deficient mice
than that produced by rhBMP-2 injection onto the wild-type
calvariae (Fig. 10 B). These data demonstrate that BMP-2–
induced bone formation is enhanced in the absence of CIZ,
indicating that CIZ suppresses BMP-signaling in vivo.
 
DISCUSSION
 
Our data revealed that deficiency in CIZ increased basal bone
mass in adult mice. This phenotype was through the enhance-
ment of bone formation in vivo, increased mineralized nodule
formation in bone marrow cells, and elevated expression lev-
els of the genes encoding osteoblastic phenotype-related
marker proteins including COL1, ALP, OPN, and OSX in
bone in vivo. CIZ deficiency also enhanced bone marrow ab-
lation-induced new bone formation in vivo as well as BMP
injection–induced de novo osteogenesis in adult mice. Thus,
CIZ acts as an inhibitor of bone formation in adult mice in
vivo at least in part through its suppression of BMP actions.
CIZ localizes at adhesion plaques, transfers into nuclear
compartments, binds to consensus DNA sequences, and acti-
vates promoters of the genes encoding enzymes that degrade
Figure 5. CIZ deficiency enhances basal ALP activity levels in bone 
marrow cells. Bone marrow cells were cultured as described in Materials 
and methods for 10 d. The media were changed every 3 d. ALP activities 
were measured in cells cultured in six wells and the values were normal-
ized against protein concentrations. Asterisk indicates statistically signifi-
cant difference (P   0.05).
Figure 6. Formation of mineralized nodules in culture is enhanced 
by CIZ deficiency. (A) Bone marrow cells were cultured in the mineraliza-
tion medium for 2 wk and at the end of the culture, mineralized nodules 
were visualized by Alizarin red-S staining. The data represent one out of 
three independent experiments with similar results using cells from differ-
ent mice. (B) Quantification of the number of the mineralized nodules in 
cultures. Asterisk indicates statistically significant difference (P   0.05). 
(C) Quantification of the number of the TRAP-positive multinucleated cells 
developed in culture. Osteoclastogenesis was conducted using bone marrow 
cells obtained from wild-type and CIZ KO mice. 
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matrix proteins (15). As CIZ is expressed in cultured osteo-
blasts (17–19), this protein was thought to be a modulator of
osteoblastic function. However, there was an ambiguity re-
garding CIZ actions in vitro because CIZ was reported to
regulate expression of osteoblast-related genes positively or
negatively depending on culture conditions (18, 19). Thus, in
vitro overexpression experiments failed to determine CIZ
function in osteoblasts. Our data in this paper conclusively in-
dicated that CIZ deficiency enhanced adult bone volume lev-
els in vivo. Therefore, CIZ is an inhibitory determinant for
adult bone mass in vivo. CIZ deficiency enhances basal as well
as BMP-induced alkaline phosphates activities in osteoblasts in
culture. This implies that in vivo observations on the eleva-
tion of basal bone mass in CIZ-deficient mice as well as CIZ
deficiency enhancement in BMP-induced bone formation on
calvaria in vivo would be reflecting cell-autonomous actions
of CIZ. Furthermore, we have observed previously in cul-
tured osteoblasts that CIZ overexpression suppressed Smad-
dependent activation of transcription (19). In the present
work, CIZ deficiency enhanced bone formation and mineral
apposition rates without altering osteoclast number and osteo-
clast surface in vivo. Therefore, CIZ suppresses adult bone
mass levels by reduction in osteoblastic activity through the
inhibition of BMP actions via interference of Smad activities.
Several signaling mechanisms have been reported to regu-
late adult bone mass in the last several years. Low-density lipo-
protein receptor-related protein 5 (LRP5) acts as a coreceptor
for Wingless-Int family member signaling, and loss of function
mutation in LRP5 gene leads to osteoporosis. Similarly,
other types of LRP5 mutation blocks the binding of dickkopf
(DKK), an inhibitor of LRP5, and leads to increase in bone
mass in humans. Another group of molecules is involved in
negative regulation of adult bone mass via suppression of
function; these include inhibitors of BMP such as Tob (21, 22).
It is intriguing that multiple molecules such as Tob and
CIZ are involved in suppression of osteoblastic functions.
Figure 7. RT-PCR analysis of the gene expression in the bone in 
WT and CIZ-deficient mice. (A) Total RNA was extracted from humeri, 
and RT-PCR was performed using primer sets for murine OPN, ALP, COL1, 
OSX, or GAPDH genes. The amplified RT-PCR products were 244 bp of murine 
COL1, 460 bp of ALP, 460 bp of OPN, 473 bp of OSX, or 452 bp of GAPDH. 
The samples were electrophoresed in a 1% agarose gel plate and stained 
with ethidium bromide to visualized the bards. (B) Quantification of the 
expression on the genes shown in A. Asterisks indicate statistically signifi-
cant difference (P   0.05).
Figure 8. CIZ deficiency enhances BMP-2–induced ALP expression 
in bone marrow cells. Bone marrow cells were cultured in the absence or 
presence of 100 ng/ml BMP-2 for 10 d. The media were changed every 3 d. 
ALP activities were measured in the bone marrow cells and the values were 
normalized against protein concentrations. Data are expressed as fold 
induction of the ALP activities relative to WT control samples. Asterisks 
indicate statistically significant difference (P   0.05). 
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Bone is the storage site for BMP and, thus, the cells in bone
could be subjected to continuous and possibly excessive ex-
posure to BMP-driven stimuli. CIZ and Tob may partly
block such excessive BMP signals and, thus, prevent abnor-
mal or ectopic bone formation. Such negative regulation of
BMP action by at least two distinct effectors, in this case
CIZ and Tob, could be an important biological back-up
pathway. This makes us speculate about the presence of
strong potency in BMP action during the determination in
adult bone mass. As deletion of even one of the two mole-
cules CIZ and Tob results in exhibition of bone phenotype,
simultaneous presence of both of the two is necessary for
normal bone mass maintenance. Furthermore, we observed
that both CIZ and Tob expression levels in osteoblasts in
cultures are enhanced by BMP treatment. Thus, these two
molecules form negative feedback circuits with BMP sepa-
rately or in parallel. It can be observed in other biological
systems that growth factors stimulate biological functions of
cells while these molecules simultaneously enhance expres-
sion of inhibitors for their own activities (23–26). The bal-
anced activities of both accelerators (stimulating cytokines)
and decelerators (their inhibitors) would determine the nor-
mal balance in the biological functions of organs (in this case,
bone). To our knowledge, CIZ is the first attachment- and
transcription-related molecule that inhibits osteoblastic func-
tion in adult bone in vivo.
BMP is an important molecule in the body in various as-
pects. BMP is required for the maintenance of bone to sup-
port the body or to protect internal organs. BMP also reg-
ulates morphogenesis during embryonic development. In
accordance with such a variety of BMP actions, numerous
groups of BMP inhibitors have been identified. One group
includes soluble BMP inhibitors such as noggin, chordin,
SOST, and gremlin, which act outside the cells. These mol-
ecules inhibit BMP signaling via binding to BMP ligands to
prevent their binding to their cognate receptors (27–29).
BMP3 binds to BMP receptor and inhibits bone formation.
Other groups consist of inhibitory Smad proteins, such as
Smad6 and Smad7. These negative Smads inhibit intracellu-
lar BMP signaling by binding to BMP receptors or regula-
tory Smads (30, 31). A recently identified group contains
proteins such as Tob, which acts as a Smad repressor to in-
hibit BMP signaling at the level of the nuclear transport or
Figure 9. New bone formation in vivo after marrow ablation is 
enhanced in CIZ-deficient mice. (A) Two-dimensional microCT images 
of the midsagittal planes of the distal regions of the femora after 10 d 
after ablation surgery in WT and CIZ-KO mice. (B) Fractional trabecular BV/TV 
was quantified based on the image analysis of two-dimensional microCT 
images of the intact and ablated femora after 10 d after ablation surgery 
in WT and CIZ-KO mice. Analyses were conducted in the rectangular area 
shown in A. Data are expressed as fold in BV/TV of ablated side bone rela-
tive to their control (nonablated side) bone. Asterisk indicates statistically 
significant difference (P   0.05).
Figure 10. CIZ deficiency enhances BMP-2–induced bone formation 
in vivo. (A) Soft X-ray image of the calvariae of WT and CIZ-KO mice after 
10 d of rhBMP-2 injection. Arrows indicate newly formed bone. (B) Quan-
tification of the amount of newly formed bone as an area based on the 
soft X-ray image of calvariae of WT and CIZ-KO mice. Asterisk indicates 
statistically significant difference (P   0.05). 
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transcription (31). CIZ is special and distinct from other pro-
teins because it localizes at adhesion plaques and simulta-
neously activates gene expression in addition to Smad mod-
ulation (19). It is also unique in terms of its localization at
nuclear matrix (15). Thus, CIZ should be considered as a
unique class of BMP inhibitor in vivo.
It is notable that CIZ deficiency did not result in major al-
terations in skeletal morphogenesis during embryonic stages.
In the case of other BMP inhibitors, such as noggin, its defi-
ciency causes hypertrophy of cartilage and severe fusion of
joints. These knockout mice do not survive after birth (31).
This may imply that CIZ deficiency could be backed up by
the presence of other BMP inhibitors during the early period
of life when embryonic development of the skeleton is taking
place. Alternatively, CIZ-deficient mice may not have an ob-
vious (major) skeletal phenotype in embryonic stage because
of the rapid growth during that period of life. Our observa-
tions revealed that CIZ action is more important in bone me-
tabolism in “adulthood” than in the embryonic stage, even
when the target is BMP. In fact, we observed that high bone
mass phenotype could be detectable even in mice of 
 
 
 
50 wk
old (unpublished data). These facts suggest that different BMP
inhibitors would have diverse roles depending on time and
location as well as cellular backgrounds. As most age-related
diseases, including osteoporosis, affect individuals who grow
and live normally up to adult stage, the roles of molecules,
such as CIZ, could be critical for considering the pathogenesis
of age-related bone diseases in human adults. CIZ-deficient
mice also revealed defects in spermatogenesis (32). However,
except for that, bone is the only organ to reveal a phenotype
in these mice. Even for males, spermatogenesis may not be a
major problem in an aged population; therefore, it would be
of interest to contemplate development of new drugs to target
against CIZ for osteoporosis in aged patients.
In conclusion, our observations demonstrate that CIZ
deficiency enhances the levels of adult bone mass and bone
formation. This was observed to be due to enhancement in
the BMP signaling pathway in vivo and in osteoblasts in a
cell-autonomous manner. Thus, CIZ would act as a critical
suppressor for BMP signaling in osteoblastic function in
adult in vivo.
 
MATERIALS AND METHODS
 
Animals.
 
CIZ-deficient mice were produced by Nakamoto et al. (32).
Wild-type and CIZ-deficient mice in a DBA 
 
 
 
 C57BL/6 F2 background
were derived from the original heterozygous cross. These mice were main-
tained as separate colonies. The mice were kept under controlled housing
condition at 24
 
 
 
C on 12:12 light/dark cycles with the light cycle starting at
7:00 a.m., fed with standard laboratory chow (MF; Oriental Yeast), and
given tap water. CIZ-deficient and wild-type female mice (8 wk old) were
used in most of the experiments. For body weight data and some of the ex-
periments, older mice were also examined. All experiments were conducted
according to the institutional guidelines for animal welfare.
 
Two-dimensional microCT analysis of bone.
 
Trabecular bone struc-
ture and bone volume (bone volume/tissue volume [BV/TV]) were exam-
ined based on two-dimensional micro X-ray computed tomography (mi-
croCT) analysis, using a microCT apparatus (Musashi; Nittetsu-ELEX).
The fractional bone volume (BV/TV) was measured in a square area of 0.8
mm
 
2
 
 (2,000 
 
 
 
m 
 
 
 
 400 
 
 
 
m) in the distal metaphyseal region of the femora
or the fourth lumbar vertebrate and was quantified using Luzex-F Image
analyzing system (Nireco). The threshold for the measurements was set at
110 for the analyses as determined previously based on the correlation to the
values to those obtained in histomorphological measurements (33).
 
ALP assay.
 
Bone marrow cells were obtained by flushing out the cells
from the medullary cavity of femora with 
 
 
 
-minimum Eagle’s medium
(
 
 
 
-MEM). The cells were rinsed, counted, and plated in 96-well plates (5 
 
 
 
10
 
4
 
 cells/well) and were cultured in 
 
 
 
-MEM supplemented with 10% FBS,
50 
 
 
 
g/ml ascorbic acid, 10 mM 
 
 
 
-glycerophosphate, and antibiotics/anti-
mycotics. In some of the cultures, the cells were treated with 100 ng/ml rh-
BMP-2. Medium was changed every 3 d, and the cells were cultured for
10 d. The cells were rinsed twice with ice-cold PBS and scraped into 10 mM
Tris-HCl containing 2 mM MgCl
 
2
 
 and 0.05% Triton X-100, pH 8.2. The
cell lysates were briefly sonicated on ice after two cycles of freezing and
thawing. Aliquots of supernatants were subjected to ALP activity measure-
ment and protein assay according to Bradford’s method. In brief, aliquots of
cell lysates were mixed with assay buffer containing 10 mM p-nitrophenyl
phosphate in 0.1 M sodium carbonate buffer, pH 10, supplemented with 1
mM MgCl
 
2
 
 and followed by an incubation at 37
 
 
 
C for 30 min. After adding
1 M NaOH, the amounts of p-nitrophenol liberated in the assay mixtures
were measured using a spectrophotometer.
 
Mineralized nodule formation assay.
 
Bone marrow cells were plated
in 24-well plates (10
 
6
 
 cells/well). The cells were cultured in 
 
 
 
-MEM sup-
plemented with 10% FBS, 50 
 
 
 
g/ml ascorbic acid, 10 mM 
 
 
 
-glycerophos-
phate, and antibiotics/antimycotics (100 U/ml penicillin G, 100 
 
 
 
g/ml
streptomycin sulfate, and 0.25 
 
 
 
g/ml amphotericin B; GIBCO BRL). Me-
dium was changed every 3 d, and the cells were cultured for 2 wk. At the
end of the cultures, the cells were fixed with 10% formalin/saline and
stained for calcium with alizarin red S to identify mineralized bone nodules.
 
Osteoclastogenesis in bone marrow cultures.
 
The proximal and distal
epiphyseal ends were removed from femora, and bone marrow cells were
flushed out. The number of total bone marrow cells was counted, and the
cells were plated in 48-well plates (0.8 cm
 
2
 
 per well) at a density of 5 
 
 
 
 10
 
5
 
cells/well. The cells were cultured in 
 
 
 
-MEM supplemented with 10%
FBS, 100 
 
 
 
g/ml antibiotics-antimycotics mixture, 10 nM 1,25(OH)
 
2
 
 vita-
min D
 
3
 
, and 100 nM dexamethasone. The medium was changed on day 3.
TRAP-positive osteoclast-like multinucleated cells (greater than two nuclei)
were counted at the end of 5 d of culture.
 
Histomorphometric analysis of bone.
 
Osteoclast number per bone
surface (Oc.N/BS, N/mm) and the percentage of osteoclast surface to bone
surface (Oc.S/BS, %) were obtained by counting TRAP-positive cells and by
measuring the area in serial 7-
 
 
 
m-thick sagittal histological sections of femora
of wild-type (
 
n
 
 
 
 
 
 8) and CIZ-deficient (
 
n
 
 
 
 
 
 6) mice (8 wk old) at 200-fold
magnification. TRAP-positive cells forming resorption lacunae on the surface
of the trabeculae and containing one or more nuclei were identified as osteo-
clasts. For in vivo fluorescent labeling, calcein (1.6 mg/kg body weight) was
intraperitoneally injected on days 0 and 4. Wild-type (
 
n
 
 
 
 
 
 8) and CIZ-defi-
cient (
 
n
 
 
 
 
 
 6) mice (8 wk old) were killed on day 6. Femora were fixed in
99.5% ethanol and embedded in methylmethacrylate without decalcification.
Sagittal histological sections (7 
 
 
 
m thick) were prepared, and the calcein im-
ages were visualized by fluorescent light microscopy. Histomorphometry of
bone sections was performed using at least six optical fields within the sec-
ondary spongiosa. The abbreviations for histomorphometric parameters were
according to the recommendation by the American Society of Bone and
Mineral Research Histomorphometry Nomenclature Committee (34).
 
RNA extraction, cDNA synthesis, and PCR.
 
Total RNA of whole
humerus was extracted according to acid guanidium thiocyanate-phenol-
chloroform method (35). First-strand cDNA was synthesized using 1 
 
 
 
g of 
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the total RNA and Molony murine leukemia virus reverse tran-
scriptase.  Primers were synthesized on the basis of the reported mouse
cDNA sequences for GAPDH (GenBank/EMBL/DDBJ accession no.
NM_008084), OPN (GenBank/EMBL/DDBJ accession no. AF515708),
ALP (GenBank/EMBL/DDBJ accession no. AF285233), COL (GenBank/
EMBL/DDBJ accession no. U38544), and OSX (GenBank/EMBL/DDBJ
accession no. AF184902). Primers for PCR reactions were as follows:
GAPDH, forward, 5
 
 
 
-ACCACAGTCCATGCCATCAC-3
 
 
 
 and reverse,
5
 
 
 
-TCCACCACCCTGTTGCTGTA-3
 
 
 
; OPN, forward, 5
 
 
 
-CGACGA-
TGATGACGATGATGAT-3
 
 
 
 and reverse, 5
 
 
 
-CTGGCTTTGGAACTT-
GCTTGAC-3
 
 
 
; ALP, forward, 5
 
 
 
-ATTGCCCTGAAACTCCAAAACC-
3
 
  
 
and reverse, 5
 
 
 
-CCTCTGGTGGCATCTCGTTATC-3
 
 
 
; COL, for-
ward, 5
 
 
 
-TTTGTGGACCTCCGGCTC-3
 
  
 
and reverse, 5
 
 
 
-AAGCAGA-
GCACTCGCCCT-3
 
 
 
; and OSX, forward, 5
 
 
 
-CTGGGGAAAGGAGGC-
ACAAAGAAG-3
 
 
 
 and reverse, 5
 
 
 
-GGGTTAAGGGGAGCAAAGTCA-
GAT-3
 
 
 
.
Amplification was performed at 21–25 cycles within a linear range.
Each cycle was set at 94
 
 
 
C for 20 s; 60
 
 
 
C for 30 s; and 72 C for 40 s in a 25-
 l reaction mixture containing 0.5  l of each cDNA, 200 mM of each
primer, 0.2 mM of dNTP, and 1 U Taq DNA polymerase (Takara). After
amplification, 10  l of each reaction mixture was subjected to electro-
phoresis to be analyzed on 1% agarose gel. The bands were visualized by
ethidium bromide staining.
Measurement of bone mineral density. Bone mineral density (g/cm2)
of the entire femora was measured based on dual-energy X-ray absorptiom-
etry (DEXA) using an apparatus specifically designed for small animals
(PIXI; GE Lunar) equipped with a laptop computer. Calibration was per-
formed using a standard block according to the manufacturer’s instruction.
In vivo bone formation by direct BMP-2 injection. Direct injection
of BMP-2 onto the calvariae was conducted as described previously (36). In
brief, rhBMP-2 (5  g in 20  l saline) was injected onto the parietal bones
of wild-type (n   8) and CIZ-deficient (n   6) mice (8 wk old). rhBMP-2
was obtained from the Genetics Institute. Injection was performed every
other day for 10 d, and the animals were killed 1 d after the last injection.
Calvariae were fixed in 4% paraformaldehyde in PBS, pH 7.4, for 24 h, re-
moved from the skull, and subjected to soft X-ray examination. X-ray im-
ages were recorded and quantified by using a Luzex-F automated image
analysis system (Nireco).
Statistical analysis. The results were presented as mean   SEM, and sta-
tistical evaluation was performed based on Student’s t test. p-values  0.05
were considered to be significantly different.
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